ZEISS Announces U.S. FDA Clearance of the QUATERA 700, a Revolution in Phaco Technology
The latest technology from ZEISS empowers surgeons with one complete, digitally integrated cataract workflow for efficiency without compromise.Jena, Germany | Dublin, USA | Carl Zeiss Meditec AG
Today, ZEISS Medical Technology announced the U.S. Food and Drug Administration (FDA) has cleared the QUATERA® 700*, a revolution in phaco technology. It includes the ZEISS patented QUATTRO Pump® which delivers an exceptional level of chamber stability independent of intra-ocular pressure (IOP) and flow.
“What excites me the most about the QUATERA 700 is the QUATTRO pump’s synchronized fluidics system and how I can have both the highest levels of efficiency, while maintaining an extremely stable chamber, independent of IOP,” said Sri Ganesh, MD, Chairman and Managing Director of Nethradhama Super Speciality Eye Hospital, Bangalore (India).
The ZEISS QUATERA 700 is designed to increase a surgeon’s workflow efficiency from the clinic to the operating room (OR), enabling one digitally integrated surgical workflow. It works as a single sterile OR dashboard integrating patient data from other systems and the microscope view, available in real-time for the OR staff.